Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Gets Pushback For Playing Doctor In Renal Stenting Coverage Proposal

This article was originally published in The Gray Sheet

Executive Summary

Stent manufacturers are urging CMS to finalize its draft coverage decision for renal stenting, though one aspect of the proposal has some wondering whether the agency is going too far in controlling physicians' interactions with patients

You may also be interested in...



Medicare Coverage News In Brief

GE T-Wave doesn't measure up: Cambridge Heart's HearTwave II microvolt T-wave alternans test would remain the only such test covered by Medicare under a Feb. 14 CMS proposal. GE Healthcare had requested that the agency expand its 2006 policy to cover the firm's Marquette MTWA test, also used to risk stratify patients who might need implantable defibrillators but with a different calculation method than HearTwave (1"The Gray Sheet" Sept. 24, 2007, p. 21); CMS says the evidence for Marquette's method is limited and not yet convincing. Perhaps more significantly, the agency notes that before finalizing its decision it will review recently reported data from the Medtronic-sponsored MASTER 1 trial, which CMS says casts doubt on the general usefulness of MTWA testing. The study could cause the agency to reassess whether MTWA, regardless of method, should be covered at all. Comments on the proposal are due March 15, and CMS will make a final decision by May 14

Medicare Coverage News In Brief

GE T-Wave doesn't measure up: Cambridge Heart's HearTwave II microvolt T-wave alternans test would remain the only such test covered by Medicare under a Feb. 14 CMS proposal. GE Healthcare had requested that the agency expand its 2006 policy to cover the firm's Marquette MTWA test, also used to risk stratify patients who might need implantable defibrillators but with a different calculation method than HearTwave (1"The Gray Sheet" Sept. 24, 2007, p. 21); CMS says the evidence for Marquette's method is limited and not yet convincing. Perhaps more significantly, the agency notes that before finalizing its decision it will review recently reported data from the Medtronic-sponsored MASTER 1 trial, which CMS says casts doubt on the general usefulness of MTWA testing. The study could cause the agency to reassess whether MTWA, regardless of method, should be covered at all. Comments on the proposal are due March 15, and CMS will make a final decision by May 14

Renal Stenting Surprise: CMS Proposes To Keep Coverage Status Quo

CMS' proposal to maintain its existing renal stenting coverage policy surprises many stakeholders who expected the agency to further restrict coverage because the data on the intervention's effectiveness is relatively weak

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel